ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Apellis, Beam ink base-editing pact to tackle complement-driven diseases
July 01, 2021Apellis Pharmaceuticals and Beam Therapeutics have forged a five-year research partnership that will apply the latter's base-editing platform toward discovering new treatments for complement-driven diseases, the companies announced Wednesday. -
Apellis Will Not Peruse Development of APL-9 for Severe COVID-19
March 10, 2021Apellis Pharmaceuticals announced the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. -
Apellis enters drug development and commercialisation deal with Sobi
October 29, 2020Apellis Pharmaceuticals has entered into a strategic collaboration with Swedish Orphan Biovitrum (Sobi) to fast-track the advancement of systemic pegcetacoplan to treat multiple rare diseases with high unmet need. -
Apellis to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria
May 27, 2020Apellis Pharmaceuticals announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020. -
Enable Injections Partners with UCB and Apellis Pharmaceuticals
November 14, 2018Enable Injections Partners with UCB and Apellis Pharmaceuticals -
Apellis sets up another phase 3 program for lead drug APL-2
August 28, 2017Trials in dry age-related macular degeneration expand Apellis Pharmaceuticals' focus beyond rare diseases.
Pharma Sources Insight January 2025
